Assembly Biosciences Announces $12.6M In Equity Financings For The Issuance Of 634,500 Shares Of Its Common Stock And Warrants To Armistice Capital LLC

6/17/24 8:02:58 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ASMB alert in real time by email

— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 —

— Anticipated near term interim data read outs include ABI-5366 Phase 1a in 3Q24 and Phase 1b in 1H25, and ABI-4334 Phase 1b by end of 2024 —

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. ("Assembly Bio") (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that it has closed the issuance of shares of its common stock and warrants to Armistice Capital LLC ("Armistice Capital"), a healthcare-focused institutional investor, and Gilead Sciences, Inc. ("Gilead"), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses.

Get the next $ASMB alert in real time by email

Date	Price Target	Rating	Analyst
9/20/2024	$2.00 → $35.00	Hold → Buy	Jefferies
9/13/2021	$3.50	Neutral	HC Wainwright & Co.
9/2/2021		Outperform → Market Perform	William Blair

Assembly Biosciences Announces $12.6M In Equity Financings For The Issuance Of 634,500 Shares Of Its Common Stock And Warrants To Armistice Capital LLC

Chat with this insight

Recent Analyst Ratings for $ASMB

$ASMB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Assembly Biosciences upgraded by Jefferies with a new price target

HC Wainwright & Co. initiated coverage on Assembly Biosciences with a new price target

Assembly Biosciences downgraded by William Blair

$ASMB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

SEC Form SC 13D/A filed by Assembly Biosciences Inc. (Amendment)

$ASMB Leadership Updates

Live Leadership Updates

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

$ASMB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Schornstein Alexander bought $145,800 worth of shares (10,000 units at $14.58), increasing direct ownership by 1% to 703,113 units (SEC Form 4)

CEO and President Okazaki Jason A sold $2,918 worth of shares (197 units at $14.81), decreasing direct ownership by 1% to 14,904 units (SEC Form 4)

Chief Manufacturing Officer White Nicole S sold $2,325 worth of shares (157 units at $14.81), decreasing direct ownership by 1% to 11,911 units (SEC Form 4)

$ASMB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Schornstein Alexander bought $145,800 worth of shares (10,000 units at $14.58), increasing direct ownership by 1% to 703,113 units (SEC Form 4)

Large owner Schornstein Alexander bought $111,631 worth of shares (9,000 units at $12.40), increasing direct ownership by 1% to 693,113 units (SEC Form 4)

Large owner Gilead Sciences, Inc. bought 179,500 shares, increasing direct ownership by 16% to 1,268,972 units (SEC Form 4)

$ASMB Press Releases

Fastest customizable press release news feed in the world

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Announces $12.6 Million in Equity Financings

$ASMB SEC Filings

Assembly Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form S-8 filed by Assembly Biosciences Inc.

SEC Form 10-Q filed by Assembly Biosciences Inc.

$ASMB Market Insights

Live Market Insights

Assembly Biosciences To Present Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors

Insiders Buying American Software And 2 Other Stocks

HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences

Recent Analyst Ratings for
$ASMB

$ASMB
Analyst Ratings

$ASMB
Large Ownership Changes

$ASMB
Leadership Updates

$ASMB
Insider Trading

$ASMB
Insider Purchases

$ASMB
Press Releases

$ASMB
SEC Filings

$ASMB
Market Insights